IN2012DN02580A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02580A
IN2012DN02580A IN2580DEN2012A IN2012DN02580A IN 2012DN02580 A IN2012DN02580 A IN 2012DN02580A IN 2580DEN2012 A IN2580DEN2012 A IN 2580DEN2012A IN 2012DN02580 A IN2012DN02580 A IN 2012DN02580A
Authority
IN
India
Prior art keywords
mglur4
allosteric
compounds useful
glutamate receptor
receptor subtype
Prior art date
Application number
Inventor
P Jeffrey Conn
Craig W Lindsley
Corey R Hopkins
Charles David Weaver
Colleen M Niswender
Darren W Engers
Yiu-Yin Cheung
Patrick R Gentry
James M Salovich
Rocco D Gogliotti
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of IN2012DN02580A publication Critical patent/IN2012DN02580A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compounds useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) and use thereof.
IN2580DEN2012 2009-09-04 2010-09-07 IN2012DN02580A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24003109P 2009-09-04 2009-09-04
PCT/US2010/048030 WO2011029104A1 (en) 2009-09-04 2010-09-07 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Publications (1)

Publication Number Publication Date
IN2012DN02580A true IN2012DN02580A (en) 2015-08-28

Family

ID=43649686

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2580DEN2012 IN2012DN02580A (en) 2009-09-04 2010-09-07

Country Status (12)

Country Link
US (1) US8779157B2 (en)
EP (1) EP2473055A4 (en)
JP (1) JP2013503909A (en)
CN (1) CN102740699A (en)
AU (1) AU2010289281A1 (en)
BR (1) BR112012004919A2 (en)
CA (1) CA2773038A1 (en)
IL (1) IL218426A0 (en)
IN (1) IN2012DN02580A (en)
RU (1) RU2012114770A (en)
SG (1) SG178999A1 (en)
WO (1) WO2011029104A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010088406A1 (en) 2009-01-28 2010-08-05 Vanderbilt University Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8759377B2 (en) * 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN105579447B (en) * 2013-09-25 2018-11-13 豪夫迈·罗氏有限公司 Ethynyl derivatives serving
EP2853532B1 (en) 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
TWI649310B (en) * 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 Acetylene derivative
UA117855C2 (en) * 2014-02-25 2018-10-10 Ф. Хоффманн-Ля Рош Аг Ethynyl derivatives
WO2016115272A1 (en) 2015-01-13 2016-07-21 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10526323B2 (en) 2015-01-30 2020-01-07 Vanderbilt University Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10227343B2 (en) 2015-01-30 2019-03-12 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2016146600A1 (en) * 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag 3-(4-ethynylphenyl)hexahydropyrimidin-2,4-dione derivatives as modulators of mglur4
US9987242B2 (en) 2015-05-05 2018-06-05 Northwestern University Treatment of Levodopa-induced Dyskinesias
ES2733468T3 (en) 2015-07-15 2019-11-29 Hoffmann La Roche Ethinyl derivatives as modulators of metabotropic glutamate receptors
SI3484889T1 (en) 2016-07-18 2020-11-30 F. Hoffmann-La Roche Ag Ethynyl derivatives
US10294222B2 (en) 2016-09-01 2019-05-21 Vanderbilt University Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10710997B2 (en) 2016-09-01 2020-07-14 Vanderbilt University Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10968227B2 (en) 2016-11-08 2021-04-06 Vanderbilt University Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2018089544A1 (en) 2016-11-08 2018-05-17 Vanderbilt University Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US11319304B2 (en) 2017-06-28 2022-05-03 Vanderbilt University Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
PE20200756A1 (en) 2017-08-16 2020-07-27 Univ Vanderbilt INDAZOLE COMPOUNDS AS MGLUR4 ALOSTERIC ENHANCERS, COMPOSITIONS AND METHODS OF TREATMENT OF NEUROLOGICAL DYSFUNCTION
CA3102326A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
CN119504747B (en) * 2024-11-26 2025-11-21 上海交通大学 Nitrogen-containing hetero quaternary carbon bi-cyclic hydantoin derivative and synthesis method thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK529378A (en) * 1978-01-09 1979-07-10 Shell Int Research anilide
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2725206B1 (en) 1994-09-29 1996-12-06 Roussel Uclaf NOVEL HETEROCYCLE SUBSTITUTED IMIDAZOLIDINES, THEIR PROCESS AND PREPARATION INTERMEDIATES, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6355664B1 (en) 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
USRE38132E1 (en) 1997-03-03 2003-06-03 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines,3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
US6335445B1 (en) 1997-03-24 2002-01-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US6809088B2 (en) 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
FR2764889B1 (en) 1997-06-20 2000-09-01 Sod Conseils Rech Applic NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP1200824B1 (en) 1999-06-15 2007-04-25 Aventis Pharmaceuticals, Inc. Solid phase synthesis of n,n-disubstituted diazacycloalkylcarboxy derivatives
WO2001007052A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2001007044A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
EP1244670B1 (en) 1999-12-21 2006-03-08 MGI GP, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
JP2004535411A (en) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー Hydantoins and related heterocyclic compounds as inhibitors of matrix metalloproteinases and / or TNF-α convertases (TACE)
IL160990A0 (en) 2001-10-01 2004-08-31 Bristol Myers Squibb Co Spiro-hydantoin compounds useful as anti-inflammatory agents
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
BR0313084A (en) 2002-07-31 2005-06-28 Euro Celtique Sa Compound, pharmaceutical composition, method for producing a compound, method of treating, preventing or ameliorating a disorder, and method of treating a mammal
US7053112B2 (en) 2002-09-24 2006-05-30 Schering Aktiengesellschaft Imidazolidinedione analogs useful as anticoagulants and antithrombotics
JP2009513539A (en) 2003-07-11 2009-04-02 ベーリンガー・インゲルハイム・フエトメデイカ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング Methods for treating or preventing central nervous system disorders using compounds having selectivity for the alpha 3 subunit of a benzodiazepine receptor
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
EP2433943B1 (en) 2004-07-01 2013-09-11 Daiichi Sankyo Company, Limited Intermediates for thienopyrazole derivatives having PDE7 inhibitory activity
UY29896A1 (en) * 2005-11-04 2007-06-29 Astrazeneca Ab NEW CHROMAN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
BRPI0715160A2 (en) 2006-08-08 2013-06-11 Sanofi Aventis arylamimoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, drugs comprising these compounds, and their use
GB0713686D0 (en) * 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
WO2009050200A1 (en) 2007-10-16 2009-04-23 Novartis Ag Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators

Also Published As

Publication number Publication date
CA2773038A1 (en) 2011-03-10
RU2012114770A (en) 2013-10-10
CN102740699A (en) 2012-10-17
EP2473055A1 (en) 2012-07-11
EP2473055A4 (en) 2013-02-13
WO2011029104A1 (en) 2011-03-10
JP2013503909A (en) 2013-02-04
AU2010289281A1 (en) 2012-04-12
IL218426A0 (en) 2012-04-30
SG178999A1 (en) 2012-04-27
US8779157B2 (en) 2014-07-15
US20120245153A1 (en) 2012-09-27
BR112012004919A2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
SG178999A1 (en) Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
MX2012013031A (en) Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction.
MY181898A (en) Heterocyclic compounds and uses thereof
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MX2010008714A (en) Amide derivatives as positive allosteric modulators and methods of use thereof.
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
GT201300164A (en) BICYCLE DERIVATIVES (3.2.1.) OCTILAMIDA AND ITS USES
MY160490A (en) Arylethynyl derivatives
MY161170A (en) Pyrimidine cyclohexyl glucocorticoid receptor modulators
MX2009007284A (en) Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts.
TN2012000195A1 (en) Solid dispersion of rifaximin
MX2009009415A (en) Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor.
MX2011014019A (en) Diazahomoadamantane derivatives and methods of use thereof.
EP2670731A1 (en) Positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor and uses thereof.
IN2012DN02876A (en)
IL187189A0 (en) Novel heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines
EP2230271A4 (en) Additive for polymerizable composition, polymerizable composition containing the same, and use of the polymerizable composition
MY158253A (en) Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
IN2012DN01379A (en)
WO2009132119A3 (en) Substituted oxazolidinones
IN2012DN05142A (en)
AU2009235634A8 (en) Substituted sulfonamide derivatives
WO2010060070A3 (en) Indolinone modulators of dopamine receptor
UA29770U (en) Use of migrepin as analgesic substance